189 related articles for article (PubMed ID: 33711386)
1. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
2. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.
Fu J; Zhang J; Chen X; Liu Z; Yang X; He Z; Hao Y; Liu B; Yao D
Theranostics; 2023; 13(2):787-809. PubMed ID: 36632213
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Promoting ATAD2 and Its Preclinical Challenges.
Liu H; Wen Q; Yan S; Zeng W; Zou Y; Liu Q; Zhang G; Zou J; Zou X
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008934
[No Abstract] [Full Text] [Related]
4. ATAD2 in cancer: a pharmacologically challenging but tractable target.
Hussain M; Zhou Y; Song Y; Hameed HMA; Jiang H; Tu Y; Zhang J
Expert Opin Ther Targets; 2018 Jan; 22(1):85-96. PubMed ID: 29148850
[TBL] [Abstract][Full Text] [Related]
5. HIF1α-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia.
Nayak A; Roy AD; Rout N; Singh SP; Bhattacharyya A; Roychowdhury A
Biochem Biophys Res Commun; 2020 Mar; 523(4):916-923. PubMed ID: 31959473
[TBL] [Abstract][Full Text] [Related]
6. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
7. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
8. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.
Gay JC; Eckenroth BE; Evans CM; Langini C; Carlson S; Lloyd JT; Caflisch A; Glass KC
Proteins; 2019 Feb; 87(2):157-167. PubMed ID: 30520161
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of AAA-domain-containing protein 2 restrains cancer stem cell properties in esophageal squamous cell carcinoma via blockade of the Hedgehog signaling pathway.
Li N; Yu Y; Wang B
Am J Physiol Cell Physiol; 2020 Jul; 319(1):C93-C104. PubMed ID: 31747529
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic potential of ATAD2 in stomach cancer and insights into the protein-protein interactions at its AAA + ATPase domain and bromodomain.
Nayak A; Kumar S; Singh SP; Bhattacharyya A; Dixit A; Roychowdhury A
J Biomol Struct Dyn; 2022 Aug; 40(12):5606-5622. PubMed ID: 33438526
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.
Wang XL; Wang S; Wu ZZ; Yang QC; Li H; Xiong HG; Wan SC; Sun ZJ
Int J Med Sci; 2020; 17(11):1598-1609. PubMed ID: 32669963
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-186 inhibits angiogenesis in retinoblastoma via the Hedgehog signaling pathway by targeting ATAD2.
Wu S; Han M; Zhang C
J Cell Physiol; 2019 Aug; 234(10):19059-19072. PubMed ID: 30993715
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2.
Dutta M; Das B; Mohapatra D; Behera P; Senapati S; Roychowdhury A
Life Sci; 2022 Jul; 301():120592. PubMed ID: 35504332
[TBL] [Abstract][Full Text] [Related]
16. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer.
Sun W; Lan X; Zhang H; Wang Z; Dong W; He L; Zhang T; Zhang P; Liu J; Qin Y
Cell Death Dis; 2018 Mar; 9(3):380. PubMed ID: 29515109
[TBL] [Abstract][Full Text] [Related]
17. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
[TBL] [Abstract][Full Text] [Related]
18. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain.
Evans CM; Phillips M; Malone KL; Tonelli M; Cornilescu G; Cornilescu C; Holton SJ; Gorjánácz M; Wang L; Carlson S; Gay JC; Nix JC; Demeler B; Markley JL; Glass KC
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502039
[TBL] [Abstract][Full Text] [Related]
19. ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.
Sun T; Du B; Diao Y; Li X; Chen S; Li Y
BMB Rep; 2019 Jul; 52(7):457-462. PubMed ID: 31186081
[TBL] [Abstract][Full Text] [Related]
20. ATAD2 drives colorectal cancer progression by regulating TRIM25 expression via a positive feedback loop with E2F transcriptional factors.
Tong Y; Li J; Peng M; Qian Q; Shi W; Chen Z; Liu B
Biochem Biophys Res Commun; 2022 Feb; 594():146-152. PubMed ID: 35085891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
